Paclitaxel and etoposide co-loaded polymeric nanoparticles for the effective combination therapy against human osteosarcoma

Abstract

BackgroundThe combination of chemotherapeutic drugs with different pharmacological action has emerged as a promising therapeutic strategy in the treatment of cancers. Present study examines the antitumor potential of paclitaxel (PTX) and etoposide (ETP)-loaded PLGA nanoparticles for the treatment of osteosarcoma.ResultsThe resulting drug-loaded PLGA NP exhibited a nanosize dimension with uniform spherical morphology. The NP exhibited a sustained release profile for both PTX and ETP throughout the study period without any sign of initial burst release. The combinational drug-loaded PLGA NP enhanced the cytotoxic effect in MG63 and Saos-2 osteosarcoma cell lines, in comparison to either native drug alone or in cocktail combinations. Additionally, NPs showed an appreciable uptake in MG63 cells in a time-based manner. Co-delivery of anticancer drugs resulted in enhanced cell cycle arrest and cell apoptosis. The results clearly showed that combinational drugs remarkably improved the therapeutic index of chemotherapeutic drugs. The greater inhibitory effect of nanoparticle combination would be of great advantage during systemic cancer therapy.ConclusionTaken together, our study demonstrated that PTX-ETP/PLGA NP based combination therapy holds significant potential towards the treatment of osteosarcoma.

CD44 targeted chemotherapy for co-eradication of breast cancer stem cells and cancer cells using polymeric nanoparticles of salinomycin and paclitaxel

“…Baek [63]. These results are consistent with few others findings on superior efficacy with combinational treatment [49,64].…”

Nanomedicine-Mediated Combination Drug Therapy in Tumor

“…For instance, co-delivery of docetaxel (DTX) and tanespimycin (17-AAG) by hyaluronic acid (HA)-modified PLGA nanoparticles had shown the highest synergistic effect in killing MCF-7, MDA-MB-231 and SCC-7 cells at the molar ratio of 2:1 (DTX:17-AGG), and this synergistic antitumor activity was also demonstrated in vivo [19]. Furthermore, Wang et al [20] developed PEGylated PLGA nanoparticles for co-encapsulating paclitaxel (PTX) and etoposide (ETP) and demonstrated that co-delivery system enhanced cell cycle arrest and apoptosis of the human osteosarcom cells and improved cytotoxic activity of chemotherapeutic drugs. Table 1.…”

“…Hyaluronic acid-decorated PLGA nanoparticles Breast cancer, squamous cell carcinoma [19] Paclitaxel and etoposide PEG-PLGA nanoparticles Osteosarcoma [20] Cisplatin and paclitaxel Folic acid modified PEG-PLGA nanoparticles Non-small lung cancer [21,22] Cisplatin and doxorubicin Transferrin modified PEG-PLGA nanoparticles Human hepatoma carcinoma [23] Combretastatin-A4 phosphate and doxorubicin mPEG-PLA nanoparticles Human nasopharyngeal epidermal carcinoma [24] Paclitaxel and tetrandrine CTAB@MSN Breast cancer [25] mPEG-PCL nanoparticles Gastric cancer [27] PEG-b-PCL nanoparticles Gastric cancer [28] Pirarubicin and paclitaxel Human serum albumin nanoparticles Breast cancer [15] Hypocrellin B and paclitaxel Hyaluronic acid-ceramide nanoparticles Lung cancer [29] Doxorubicin and paclitaxel mPEsG-b-PLG-b-PLL/DOCA nanovehicle Non-small cell lung cancer [30] PEG-PLGA and PEG-PLA nanoparticles have also been chemically altered to improve tumor targeting. For example, He et al [21,22] utilized folic acid (FA)-modified PEG-PLGA nanoparticles for the co-delivery of cisplatin (CDDP) and PTX.…”

PhytoNanotechnology: Enhancing Delivery of Plant Based Anti-cancer Drugs

“…The cell cycle progression studies indicated that the co-encapsulated PTX–ETP PLGA NPs arrested maximum number of cells at the same concentration as individual free drugs, the apoptosis fraction being almost double than the individual drugs in the early and late apoptosis phases of the cycle. These PTX–ETP PLGA NPs exhibited synergistic activity against osteosarcoma cancer cells (Wang et al, 2015). …”